Lukas Delasos, DO
Hematology & Oncology · Cleveland, OHNPI 1952835696
Payments from drug & device makers
Across 14 payments — averaging $17,476 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$219K
- Mirati Therapeutics, Inc.$15K
- Amgen$6K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Eli Lilly$566
- Seagen Inc.$173
- plus $487 from 5 others
What the payments were for
- Consulting fees$3,27083%
- Food & beverage$42411%
- Education$2506%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $218,760 |
| Mirati Therapeutics, Inc. | 1 | $14,900 |
| Amgen | 2 | $6,489 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,284 |
| Eli Lilly | 1 | $566 |
| Seagen Inc. | 2 | $173 |
| Beone Medicines USA, Inc. | 1 | $150 |
| G1 Therapeutics, Inc. | 1 | $125 |
| Novartis | 1 | $98 |
| Lilly USA, LLC | 1 | $77 |
| AstraZeneca | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$244,659 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 12 | $1,979 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cleveland
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
- Nathan PennellCleveland$3.8M
- Ankit ManglaCleveland$3.3M
- David BajorCleveland$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.